Drug combo for AML that didn't respond to venetoclax
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (cladribine, low-dose cytarabine, and venetoclax) for people with AML that has not responded to standard treatment, particularly if they have already taken venetoclax. The goal is to see if this new combination can help control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have AML that has come back or not responded to treatment, or AML that developed from a prior blood condition like MDS or MPN, AND you must have taken venetoclax before.
- You should be generally active (able to do most daily activities, even if you need some rest).
- Your liver and kidneys need to be working well enough based on blood tests.
- If you could become pregnant, you must agree to use effective birth control during treatment and for 6 months after, and not breastfeed during treatment and for 10 days after.
- You cannot have a type of AML called APL (acute promyelocytic leukemia) or have had a stem cell transplant with severe graft-versus-host disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (lisafotoclax, decitabine, and homoharringtonine) for people with AML who have already tried venetoclax and azacitidine and it didn’t work. The goal is to find a treatment that might work when the first therapy fails.
This trial tests a combination of three drugs (aclarubicin, azacitidine, and venetoclax) for adults with acute myeloid leukemia (AML) who either cannot have intensive chemotherapy or whose AML has come back after treatment. The goal is to see if this combination is safe and works better.
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
This trial tests a combination of two drugs, venetoclax (a pill) and decitabine (given by IV), for people with AML that has not responded to initial treatment or has come back. The goal is to see if this combination can help control the leukemia again.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.